49results about How to "Reduce reperfusion injury" patented technology

A method and apparatus for the prevention and treatment of reperfusion injury following the reperfusion of acute MI which includes modulation of coronary blood flow or oxygen delivery following the reperfusion of the infarct with a catheter placed in the coronary artery or vein.

A method and apparatus for retroperfusing cerebral venous vasculature with autologous venous blood through a percutaneous entry site which incorporates a double-lumen catheter, a self-inflating pressure-regulated balloon mounted on the catheter and a perfusion outflow region either distal to the balloon for direct perfusion into the superior sagittal sinus, or proximal to the balloon for perfusion into the transverse sinus near the junction of the superior sagittal sinus.

The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.

A system and method in accordance with the present invention provides a infusion catheter that is flexible, has such a smooth traction and a low profile to minimize break up of the obstruction when crossing it, can access distal vasculature quickly, is easy to use and readily to be implemented in the conventional PCI. Another object is to provide a method that can be performed within a short period of time and employs the catheter described herein to infuse a therapeutic agent distally to the obstruction before it is removed as a means of reducing reperfusion injury, protecting distal vasculature and microcirculation, preserving myocytes, reducing infarct size and ischemic damages in the heart, brain, lung, liver, kidney and limb. Another object is to provide complementary feature options to the infusion catheter and the aspiration catheter to improve the speed and quality of the vessel clearance.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

A system including a catheter and an expandable member. The catheter includes an independent inflation lumen and an separate independent deflation lumen capable of sequential inflation and deflation of an expandable member in rapid succession, such as less than five seconds.

A method of reducing reperfusion injury in mammalian tissue comprising contacting the tissue with a protein phosphatase 2A (PP2A) inhibitor having the structure:

Disclosed is a transportable apparatus that maintains a large volume of a cold solution at a preset low temperature and rapidly delivers it to an irresuscitable patient's thoracic aorta at a preset and controlled flow rate, while monitoring pressure and eliminating the introduction of air embolisms into the patient, for the purpose of inducing profound hypothermia and suspended animation until proper treatment of the patient is available. The induction of suspended animation is intended for preservation of viability of the brain, heart, and organs for subsequent repair and resuscitation or for organ harvesting. The procedure may be performed by emergency personnel on the scene of an accident and / or while the patient is being transported in an emergency vehicle, or while in a hospital.

The invention discloses an application of an polypeptide in medicines for preventing or treating myocardial ischemia-reperfusion injury related diseases, and belongs to the field of biomedicines. The amino acid sequence of the polypeptide is SEQ ID NO.1 or SEQ ID NO.2. The polypeptide can substantially reduce the myocardial infarction area in myocardial ischemia-reperfusion injury, can be used as a medicine for preventing or treating the myocardial ischemia-reperfusion injury related diseases, and has clinic application values.

Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue and / or the bloodstream.

A method of treatment of cancer with a formulation of liposomally encapsulated glutathione, that is preferably used orally, increases the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic “fuel supply” that supports cancer cells, and without which the cells can die out. The method prevents the oxidative stress that damages normal support cells such as stromal fibroblast cells. By blocking the “fuel supply,” the invention can protect, prevent and reverse these cells from the steps of autophagy and mitophagy, that results in the cells decreasing the normal production of ATP for energy and using aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells.

The invention discloses a pharmaceutical composition of chlorprothixene and a protective effect on cerebral ischemia reperfusion injury. The pharmaceutical composition of chlorprothixene provided by the invention contains chlorprothixene and a novel structure natural product compound (I) separated from Radix Adenophorae. Chlorprothixene and the natural product can reduce cerebral ischemia reperfusion injury when they act individually, and the two can be combined to achieve a better control effect on cerebral ischemia reperfusion injury, thus being able to be developed into drugs for control of cerebral ischemia reperfusion injury. Compared with the prior art, the pharmaceutical composition provided by the invention has outstanding substantial characteristics and remarkable progress.

The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.

The invention discloses a medicine compound for treating myocardial ischemia reperfusion of a rat, belonging to the technical field of the medicine compound for preventing and controlling myocardial infarction. The medicine compound for treating myocardial ischemia reperfusion of the rat comprises the following ingredients: 5-15 parts of astragalus extract, 5-10 parts of salvia miltiorrhiza, 2-5 parts of carthamus tinctorius, 1-3 parts of rhodiola rosea, 0.25-0.75 part of procyanidine, 0.25-0.75 part of adiponectin and 1-2 parts of puerarin. According to the medicine compound for treating myocardial ischemia reperfusion of the rat and an application method thereof provided by the invention, the myocardial ischemia reperfusion injury can be obviously relieved; procyanidine which has the effect of relieving inflammation and oxidative stress is added into the medicine compound, so that the oxidation resistance of a body can be promoted; adiponectin has the functions of regulating glucolipid metabolism, resisting inflammation and resisting atherosclerosis; the medicine compound has the function of protecting rat myocardium; the medicine compound can greatly reduce the apoptosis rate of the cells and protect the complete form of the cells.

The invention provides a myocardial-cell-derived exosome based on Tongxinluo pretreatment and a preparation method thereof. The preparation method comprises: pretreating myocardial cells with Tongxinluo, subjecting the pretreated myocardial cells to hypoxia / reoxygenation, and collecting an exosome secreted by the myocardial cells. The myocardial-cell-derived exosome effective in reducing the apoptosis of myocardial microvascular endothelial cells to alleviate myocardial Ischemia reperfusion injury can be prepared via the preparation method.

The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.

The invention discloses a kidney-tonifying traditional Chinese medicine composition for treating ischemic brain injury and a preparation method thereof, relates to the field of traditional Chinese medicines, and aims to solve the problems of poor treatment effect and single treatment mode of a traditional Chinese medicine for treating cerebral ischemic diseases by tonifying kidney and promoting brain circulation. The composition consists of radix rehmanniae preparata, fructus corni, fructus lycii, semen cuscutae, tortoise-plastron glue, rhizoma chuanxiong, ginseng, herba epimedii, poria cocosand herba cistanche, is combined with a traditional Chinese medicine fumigant and an auricular point patch for use, and has a remarkable curative effect on cerebral ischemic diseases. The compositionis applied to the field of brain injury treatment.

The invention relates to the field of medical equipment and provides a flow-limiting external vascular stent. The stent made of an insoluble and non-degradable biocompatible material is of a tubular structure, and an opening for embedding of a blood vessel is axially formed in a stent wall. Due to the fact that the effective inner diameter of the hollow tubular structure of the stent is smaller than the effective outer diameter of the blood vessel which is embedded in the inner wall of the tubular structure from an open-lap seam, compression of the external blood vessel stent upon the blood vessel is formed to reduce the outer diameter of the blood vessel and compress the blood vessel to reduce the inner diameter, and the corresponding treatment purpose is achieved by reducing blood supply of the blood vessel to tissue.

The invention relates to an application of a compound with the tail end being branched chain fatty acid and a compound of a derivative for preparing medicine curing ischemia and reperfusion injury of tissues or organs of people. The ischemia and reperfusion injury comprises cerebral ischemia and reperfusion injury caused by operations of cerebrovascular disorder, cardiac arrest and cardio-pulmonary resuscitation, and ischemia and reperfusion injury of therapy of miocardial infarction, ischemia of intestine, hepatic ischemia and thrombolysis, operations on vessels of heart, and histoorgan transplantation.

A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized in combination with other therapeutic agents to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position , the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist alone or in combination with other therapeutic agents elute from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury.

The invention discloses an application of glucogalactooligosaccharide in preparation of a medicine for treating and / or preventing ischemia-reperfusion injury. The glucogalactooligosaccharide disclosed by the invention can be used for remarkably relieving postoperative liver injury, kidney injury, brain injury and the like of ischemia reperfusion mice, is safe and non-toxic, has a strong drug effect, and has a very good medicinal prospect in prevention and treatment of ischemia reperfusion injury.

The present invention relates to methods and compositions related to the use of enzymes of the allene oxide synthase family for reducing myocardial ischemia reperfusion injury associated with myocardial infarction, thrombolysis, angioplasty and coronary bypass surgery. The methods of the invention comprise administration of allene oxide synthases, which are capable of eliminating lipid hydroperoxides, as a potent cardioprotective agent. The invention is based on the discovery that administration of allene oxide synthase following severe global ischemia stimulates cardiac recovery.

The invention relates to an oral sustained-release solid preparation with vinpocetine as an active ingredient. It is an oral sustained-release solid preparation made from vinpocetine and its salts and pharmaceutically acceptable auxiliary materials through preparation technology. The oral sustained-release solid preparations involved in the present invention include but not limited to tablets, capsules, granules and sustained-release pellets. The quality is stable, controllable, safe and effective.

This invention proposes an agent to block the “fuel supply” that energizes cancer cell growth by protecting surrounding cells to the cancer, particularly stromal fibroblast cells. The invention disables the products of surrounding cells useable for energy conversion by the cancer cell thereby crippling the cell and disabling its growth process. This application describes the use of a formulation of liposomally encapsulated glutathione that is preferably used orally to increase the level of glutathione in tissues in order to prevent and reverse the metabolic changes in cells that results in the formation of the metabolic fuel that supports cancer cells and to prevent the oxidative stress that damages normal support cells such as fibroblasts and can prevent and reverse these cells from the steps of autophagy and mitophagy that results in the cells decreasing the normal mitochondrial production of ATP for energy and resorting to the use of aerobic glycolysis for energy production. The use of oral liposomally encapsulated glutathione will maintain the presence and normal function of caveolin in fibroblast and other cells, thus preventing their conversion to autophagic tumor stromal cells. By stopping the formation of autophagic cells, the production of the metabolic fuel needed by cancer cells is stopped, which results in the death of the cancer cells. Compositions using liposomally encapsulated glutathione and other compounds that enhance the favorable effects of liposomal glutathione on cancer disease are referenced.

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.

The invention discloses a drug delivery system for percutaneous coronary intervention, which comprises: adenosine; infusion consumables for adenosine infusion; used for catalyzing excessive adenosine metabolism in the body, and Adenosine kinase that activates the downstream AMPK pathway; infusion consumable for infusion of adenosine kinase. The drug delivery system can reduce the retention of adenosine after percutaneous coronary intervention in patients with adenosine kinase mutation or insufficient activity, increase the activity of adenosine kinase, thereby reducing myocardial reperfusion injury and improving the myocardial reperfusion protective effect of adenosine.

The present invention provides methods for the inhibition of reperfusion injury by treatment with Grammastola spatulata mechanotoxin4 (GsMTx4). The GsMTx4 may be delivered to the ischemic tissue in an individual by any means prior to, during or after ischemia reperfusion injury.

The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.

The invention provides a fusion protein TNB with effects of thrombolysis and cerebral protection and coding genes and application of the fusion protein, and discloses a fusion protein with dual effects of thrombolysis and neuroprotection and coding genes and application of the fusion protein. The amino acid sequence of the fusion protein is shown in SEQ ID No. 2. In addition, the invention also discloses nucleotide sequences which are used for encoding the fusion protein, and a preferable nucleotide sequence is shown in SEQ ID No. 4. The pharmacological activity of the fusion protein is evaluated by using a rat arteriovenous bypass thrombolysis model and an embolization model of an artery in a mouse thromboembolic brain, and it is shown that the fusion protein has a good thrombolytic effect and a function of reduction of ischemic brain injuries. A new technology is provided for treatment of acute ischemic stroke and other thrombotic diseases, and the fusion protein has broad application prospects.